Generated Narrative: Composition 399871 version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en Profile: ParticipantFlowReport url: https://fevir.net/resources/Composition/399871 identifier: FEvIR Object Identifier/399871, FEvIR Linking Identifier/NCT03421379-participant-flow-report status: Final type: Participant Flow Report date: 2025-12-11 20:35:21+0000 author: [No author listed.] title: Participant Flow Report for NCT03421379 custodian: Computable Publishing LLC RelatesTos - Type Target[x] * Cite As Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json. Generated Narrative: Group #FG000 Profile: ExposureGroup name: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride description: A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2. type: Person membership: Enumerated Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03421379 false Generated Narrative: Group #FG001 Profile: ExposureGroup name: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder description: A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2. type: Person membership: Enumerated Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03421379 false Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: STARTED at Period 1 Statistics - StatisticType Quantity * Count 34 Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: STARTED at Period 1 Statistics - StatisticType Quantity * Count 41 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: Received at Least One Dose of Study Drug at Period 1 Statistics - StatisticType Quantity * Count 33 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: Received at Least One Dose of Study Drug at Period 1 Statistics - StatisticType Quantity * Count 39 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: COMPLETED at Period 1 Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: COMPLETED at Period 1 Statistics - StatisticType Quantity * Count 37 Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: NOT COMPLETED at Period 1 Statistics - StatisticType Quantity * Count 2 Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: NOT COMPLETED at Period 1 Statistics - StatisticType Quantity * Count 4 Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: Reasons for withdraw at Period 1 statistic statisticType: Count category: Withdrawal by Subject quantity: 0 statistic statisticType: Count category: Physician Decision quantity: 1 statistic statisticType: Count category: Did not receive treatment quantity: 1 Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: Reasons for withdraw at Period 1 statistic statisticType: Count category: Withdrawal by Subject quantity: 1 statistic statisticType: Count category: Physician Decision quantity: 1 statistic statisticType: Count category: Did not receive treatment quantity: 2 Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: STARTED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: STARTED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 37 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: COMPLETED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: COMPLETED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 37 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: NOT COMPLETED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 0 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days) status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: NOT COMPLETED at Washout Period (3 to 14 Days) Statistics - StatisticType Quantity * Count 0 Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: STARTED at Period 2 Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: STARTED at Period 2 Statistics - StatisticType Quantity * Count 37 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: COMPLETED at Period 2 Statistics - StatisticType Quantity * Count 32 Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: COMPLETED at Period 2 Statistics - StatisticType Quantity * Count 37 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG000 title: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Nasal Powder/Glucagon Hydrochloride variableDefinition variableRole: Outcome observed: NOT COMPLETED at Period 2 Statistics - StatisticType Quantity * Count 0 Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG001 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG001 title: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2 status: Active author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ParticipantFlowEvidence variableDefinition variableRole: Population observed: Glucagon Hydrochloride Solution/Glucagon Nasal Powder variableDefinition variableRole: Outcome observed: NOT COMPLETED at Period 2 Statistics - StatisticType Quantity * Count 0
NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride
A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.
Research Study from which this is a flow group
NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder
A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1
Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
Glucagon Nasal Powder/Glucagon Hydrochloride
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1
Glucagon Hydrochloride Solution/Glucagon Nasal Powder
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1
Received at Least One Dose of Study Drug at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)
STARTED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)
COMPLETED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)
NOT COMPLETED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2
ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2
ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2
Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json.
Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.
Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder
[No data.]